Searchable abstracts of presentations at key conferences in endocrinology

ea0014p158 | (1) | ECE2007

Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumors

Pawlikowski Marek , led Beata , Winczyk Katarzyna

Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumorsAngiotensin II is well known to affect the adrenal cell growth and function. Angiotensin receptors AT1 and AT2 were found to be present in the normal adrenal gland. However, the data on the expression of angiotensin receptors in the adrenal tumors is very scarce.To overcome this gap, the paraffin sections of the adrenal cortical tumors and of pheoch...

ea0035p1097 | Thyroid Cancer | ECE2014

Do the poorly differentiated and undifferentiated thyroid carcinomas could be the next candidates to somatostatin analoques treatment?

Pisarek Hanna , Pawlikowski Marek , Marchlewska Magdalena , Minias Radoslaw , Winczyk Katarzyna

Introduction: The multimodal management of poorly differentiated thyroid carcinomas (PDTC) and anaplastic carcinomas (ATC) include surgical thyroidectomy, radioiodine treatment, and cytotoxic chemotherapy. Patients with distant metastases which do not respond to radiotherapy could be treated with new therapeutic possibilities like tyrosine kinase inhibitors. PPARγ or mutant P53 are also candidates to PDTC and ATC treatment. Somatostatin and its analogs, demonstrate antipr...

ea0035p560 | Endocrine tumours and neoplasia | ECE2014

Expression of FSH hormone receptors in pituitary adenomas: a marker of tumour aggressiveness?

Pawlikowski Marek , Kunert-Radek Jolanta , Jaranowska Maria , Radek Maciej , Swietoslawski Jacek , Winczyk Katarzyna

Background: In our earlier study we found that pituitary adenomas, like other human tumours, express ectopically follicle stimulating hormone receptors FSH in intratumoral blood vessels endothelia and/or tumoral cells. The aim of the present paper is to provide the more detailed data on FSHR expression in different subtypes of pituitary adenomas and to evaluate its possible role as a prognostic and/or predictive biomarker in these tumours.Material and me...

ea0035p565 | Endocrine tumours and neoplasia | ECE2014

Effect of thiazolidinediones: PPARγ agonists on hormones secretion by cells of human adrenocortical cancer in vitro

Fuss-Chmielewska Julita , Lawnicka Hanna , Swietoslawski Jacek , Beda-Maluga Karolina , Winczyk Katarzyna

Introduction: Adrenocortical carcinoma (ACC) is characterized by the high malignancy of the lesion, poor prognosis and high mortality rate. The surgical treatment and available chemotherapy have generally low efficacy so the search for new therapeutic options is still necessary. Some research indicated that thiazolidinediones (TZDs)–synthetic ligands of peroxisome proliferator-activated receptor γ (PPARγ) have oncostatic action on neoplasm, including endocrine t...

ea0035p904 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Alternative method of macroprolactin evaluation as a cause of hyperprolactinaemia

Beda-Maluga Karolina , Pisarek Hanna , Swietoslawski Jacek , Fuss-Chmielewska Julita , Winczyk Katarzyna

Introduction: Macroforms of prolactin (PRL), the most often macroprolactin (MaPRL), may be the cause of about 25% cases of laboratory diagnosed hyperprolactinaemia. Macroprolactin is usually quantified by polyethylene glycol precipitation, however, the cut-off value (that means the calculated recovery ratio of monomeric PRL) has not been precisely determined and has rather unsatisfactory diagnostic specificity. Therefore, it is suggested that the evaluation of hyperprolactinae...

ea0014p160 | (1) | ECE2007

Inhibitory effect of rosiglitazone – PPARgamma receptor ligand on growth of human adrenocortical tumor cells in vitro

Winczyk Katarzyna , Lawnicka Hanna , Fuss-Chmielewska Julita , Kolomecki Krzysztof , Kuroszczyk Jacek , Pawlikowski Marek

Introduction: The peroxisome proliferator-activated receptors gamma (PPARγ) are nuclear receptors which are detected in normal and pathological tissues. Our earlier study showed the overexpression of PPARγ in human adrenal tumors and pituitary adenomas in comparison to normal glands. The in vitro experiments indicated that ligands of PPARγ inhibit growth of many tumors including pituitary adenomas, thyroid cancers and adrenal carcinomas. However, the data...